Business
Starpharma (ASX:SPL) share price dips on quarterly update // The Motley Fool Australia
The Starpharma Holdings Limited (ASX: SPL) share price has dipped slightly today after the company released its quarterly cashflow and activities report for the quarter ended 31 December 2020.
Starpharma is a global biopharmaceutical company that develops pharmaceutical and medical products based on proprietary polymers called dendrimers. Dendrimers are man-made nanoscale compounds that can be used both to enhance existing health products and as entirely new products.
The company is presently developing Viraleze, an antiviral nasal spray for COVID-19 that is complementary to vaccines and other preventative measures.
Here are some highlights from the company’s quarterly update.
Starpharma developments during the December…
-
Noosa News24 hours agoE-bikes shouldn’t be banned. The illegal ones are already illegal
-
General20 hours agoChina was the big disruptor in our region. Now the US is determined to take that title
-
General20 hours agoSpaceX to invest $3 billion in Musk’s xAI startup
-
Noosa News12 hours ago“Hidden gem”: last chance for renovated bayside homes below $1m